India Biopharmaceutical Market Size, Share, By Type (Monoclonal Antibody, Interferon, Insulin, Growth & Coagulation Factor, Erythropoietin, Vaccine, Hormone, and, Others) and By Application (Oncology, Blood Disorder, Metabolic Disease, Infectious Disease, Cardiovascular Disease, Neurological Disease, Immunology, and Others) - Trends, Analysis, and Forecasts till 2034

India Biopharmaceutical Market Size was valued at USD 2.1 billion in 2024 and is expected to grow at a CAGR of 24.8% to reach USD 15.8 billion by 2034.

India Biopharmaceutical Market is one of the fastest-growing biotechnology segments in India. A biopharmaceutical, also known as a biologic medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological Applications. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood Types, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. The significant biopharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.

The biopharmaceutical market in India has grown well over the decade, the practice of manufacturing pharmaceutical products using organic and natural living content has been widespread.

Key Drivers of India Biopharmaceutical Market:   

Professionalism in research and development

• With the help of highly experienced and qualified scientists the studies regarding research and development of new drug or compounds have been beneficial for India biopharmaceutical industry. Many Industries provide opportunity for youth to have a contribution to the research and development of biopharmaceutical drugs. Highly skilled workmanship makes it a driving factor of market

Growing Investor Demand

• Main driving factor for the market is growing investor demand. Many of the projects for biopharmaceuticals have been funded by government giving it an acceleration in the growth of biopharmaceutical Industry proving economic growth at the same time. The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India program, for collaboration of industrial organizations and academic organizations over the next five years. This program is considered to act as a significant action of the Government in its way of boosting bio-pharmaceutical production in the country.

India Biopharmaceutical Market Restraints:

High Implementation Costs

• Implementing cost for manufacturing of biopharmaceuticals is relatively higher than other pharmaceutical products as it requires living raw material for the manufacturing of drugs. It requires sample cost, techniques for making the sample usable and many other factors like high implementation cost of machinery, lab equipment and others

Lack of infrastructural support

• The inadequate infrastructure of the biopharmaceutical industry, including inadequate government-sponsored laboratory space, consumables, chemical Types, and equipment, significantly impedes the market's expansion.

India Biopharmaceutical Market is segmented based on based on by Type and Application.

Type Insight

• Monoclonal Antibody – Targeting particular molecules within the body is the purpose of monoclonal antibodies. Scientists can make vast amounts of identical antibodies by cloning a specific immune cell in the lab. These antibodies can be genetically modified to attach to and recognize certain proteins, including those on viruses or cancerous cells. They are employed in medicine for research, diagnostic procedures, and focused therapy.
• Interferon- Proteins called interferons are secreted by cells in reaction to pathogens, viruses, or other dangers. They are essential to the immune system because they alert nearby cells to strengthen their defences against infection. In addition to preventing viral replication within infected cells, interferons can also slow the spread of infection. They are occasionally used to treat certain malignancies and viral infections.
• Insulin- The pancreas secretes the hormone insulin, which controls blood glucose (sugar) levels. It makes it possible for cells to take in glucose from the blood and store it for later consumption or use as fuel. Diabetes is characterized by either insufficient insulin production by the pancreas or improper insulin cellular response. High blood sugar can result from this imbalance. Insulin injections are frequently necessary for diabetic people in order to control their blood sugar levels and avoid problems.
• Growth Coagulation Factor-Proteins called growth factors control how cells divide, proliferate, and develop inside the body. They are crucial for wound healing, tissue repair, and the preservation of healthy tissues. Proteins called coagulation factors aid in the blood clotting process, which halts bleeding following trauma. For the purpose of preserving general health and treating illnesses or injuries, both kinds of elements are essential.
• Erythropoietin- The kidneys release the hormone erythropoietin (EPO) in reaction to low blood oxygen levels. It encourages the production of red blood cells in the bone marrow, which distribute oxygen throughout the body. Medical professionals utilize synthetic forms of erythropoiesis protein (EPO) to treat diseases like anemia, which is characterized by a lack of red blood cells, or to assist patients receiving specific treatments that lower the production of red blood cells.
• Vaccine-Vaccines are drugs that, without actually causing the disease, stimulate the immune system to create immunity to a particular disease. The disease-causing bacteria is typically present in them in weakened or inactive forms, as well as in fragmented or artificially replicated forms. Vaccination aids in the development of the body's memory of the microbe, enabling it to generate a prompt and potent immune response in the event that the disease-causing agent is subsequently encountered. Vaccines have played a major role in stopping the spread of several infectious diseases.
• Hormone- Hormones are chemical messengers that the body produces through a variety of organs and glands. Numerous physiological functions, such as growth and development, metabolism, mood, and reproduction, are regulated by them. Following their release into the bloodstream, hormones go to their intended organs or tissues and bind to particular receptors to provide their desired effects. Hormones include things like insulin, which controls blood sugar, testosterone and estrogen, which control sexual development and function, and adrenaline, which gets the body ready for a "fight or flight" reaction. For general health and wellbeing, hormonal balance is essential.

Application Insights

• Oncology-Oncology in biopharmaceuticals focuses on the creation of medications and treatment plans for cancer. Targeted therapies, immunotherapies, and chemotherapeutic medications are some examples of these treatments. They aim to suppress or eradicate cancer cells with the least amount of harm to healthy cells.
• Blood Disorders-Haemophilia, thrombosis, and anemia are among the problems that biopharmaceuticals for blood disorders treat. Recombinant proteins or antibodies that can control blood clotting, increase the production of red blood cells, or stop aberrant clot formation are frequently used in these medications.
• Metabolic Diseases- Metabolic disease-related biopharmaceuticals address problems such as obesity, diabetes, and uncommon genetic disorders that impact metabolism. These include medications that alter metabolic pathways, enzyme replacement treatments for genetic illnesses, and insulin and diabetes.
• Infectious Diseases- In the treatment of infectious disorders, biopharmaceuticals fight pathogens such as bacteria, viruses, fungus, and parasites. These include monoclonal antibodies to neutralize bacteria, medicines and antivirals to treat infections, and vaccines to prevent infections.
• Cardiovascular Diseases-The goal of biopharmaceuticals for cardiovascular disorders is to address ailments like dyslipidemia, heart failure, and hypertension. These include drugs that control blood pressure, enhance cardiac performance, and control cholesterol levels; these drugs frequently work by inhibiting enzymes or modulating receptors.
• Neurological Diseases-Neurological diseases such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease are treated with biopharmaceuticals. These comprise neuroprotective medicines, medications that target neural circuits, and biologics that control immune responses in the nervous system.
• Immunology- Immunology in biopharmaceuticals focuses on treating problems including autoimmune diseases (like lupus and rheumatoid arthritis), inflammatory diseases (like Crohn's disease), and allergies where the immune system is involved. Biologics, which target particular immune cells or cytokines implicated in disease pathology, are examples of drugs.

India Biopharmaceutical Market Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024-2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Monoclonal Antibody, Interferon, Insulin, Growth & Coagulation Factor, Erythropoietin, Vaccine, Hormone By Application- Oncology, Blood Disorder, Metabolic Disease, Infectious Disease, Cardiovascular, Disease Neurological Disease, Immunology
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the India Biopharmaceutical Market report based on By Type and Application:

India Biopharmaceutical Market, By Type:

• Monoclonal Antibody
• Interferon
• Insulin
• Growth
• Coagulation Factor
• Erythropoietin
• Vaccine
• Hormone

India Biopharmaceutical Market, By Application:

• Oncology
• Blood Disorder
• Metabolic Disease
• Infectious Disease
• Cardiovascular Disease

The key players operating the India Biopharmaceutical market includes Biocon Ltd.,Cadila Healthcare Ltd., Dr Reddy’s Laboratories Ltd., Panacea Biotech Ltd., Wockhardt Ltd., GSK Pharmaceuticals Ltd., Bharat Biotech International Ltd., and Bharat Serums and Vaccines Ltd.

• In February 2017, Cipla, Serum Institute launch Hepatitis B vaccine. Global CEO Umang Vohra said the agreement will enable Cipla to provide affordable vaccines for a chronic disease like Hepatitis B. Cipla's strong marketing network and reach will ensure maximum accessibility of the vaccines in India. 95 percent of those who receive this vaccine will not acquire chronic Hepatitis B. Three doses of the vaccine are administered; the first is given during the first month after the first dosage, and the second is given six months following the first. The recipient of the vaccination can be shielded from this virus for many years. Furthermore, a decrease in the incidence of liver cirrhosis and liver cancer is anticipated.

• Abbott Laboratories*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• General Electric
• Biocon Ltd.
• Cadila Healthcare Ltd.
• Dr Reddy’s Laboratories Ltd.
• Panacea Biotec Ltd
• Wockhardt Ltd.
• GSK Pharmaceuticals Ltd.
• Bharat Biotec International Ltd.
• Bharat Serums and Vaccines

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Type
  • Market Snippet, By Application
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
  • Monoclonal Antibody

• Overview

• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Interferon
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Insulin
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Growth and coagulation factor
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Erythropoietin
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Vaccines
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Hormones
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Application, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Blood disorders
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Metabolic disorders
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Infectious Disease
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cardiovascular Disease
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Abbott Pharmaceuticals
• General Electric
• Biocon Ltd.
• Cadila Healthcare Ltd.
• Dr Reddy’s Laboratories Ltd.
• Panacea Biotec Ltd
• Wockhardt Ltd.
• GSK Pharmaceuticals Ltd.
• Bharat Biotec International Ltd.
• Bharat Serums and Vaccines

The Last Word

• Future Impact
• About Us
• Contact